GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Eltrombopag Olamine

Company
National Heart, Lung, and Blood Institute (NHLBI)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
14 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

14 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Eltrombopag Olamine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03844360

    Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

    Not yet reported Wei Zhao 1500 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Hematological Neoplasms
    View official trial listing →
  • Recruiting NCT NCT04304820

    Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 80 participants Est. completion 2033-12-18 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Recruiting NCT NCT04518475

    Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 224 participants Est. completion 2030-08-10 1 site Stand-alone
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Recruiting NCT NCT04600960

    Eltrombopag for Chemotherapy-induced Thrombocytopenia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Chemotherapy-induced Thrombocytopenia, Eltrombopag
    View official trial listing →
  • Recruiting NCT NCT04993885

    Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 52 participants Est. completion 2025-09-30 1 site
    Other conditions: Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
    View official trial listing →
  • Recruiting NCT NCT05961410

    Eltrombopag for Peripheral Blood Stem Cell Harvest

    Not yet reported National Taiwan University Hospital 46 participants Est. completion 2026-03-01 1 site Stand-alone
    Other conditions: Lymphoma, Peripheral Blood Stem Cell Transplantation
    View official trial listing →
  • Recruiting NCT NCT06287268

    Revolade Tablets Specified Drug-use Survey

    Novartis Pharmaceuticals 10 participants Est. completion 2028-10-31 17 sites
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Recruiting NCT NCT06345495

    High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2029-01-01 1 site Stand-alone
    Other conditions: Splenomegaly, Myelofibrosis
    View official trial listing →
  • Recruiting NCT NCT06479291

    The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

    Not yet reported Yunfeng Cheng 126 participants Est. completion 2026-12 7 sites Stand-alone
    Other conditions: Immune Thrombocytopenia With Positive ANA Antibodies
    View official trial listing →
  • Recruiting NCT NCT06531018

    Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

    Not yet reported, Not yet reported Renata PLC 100 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Primary Immune Thrombocytopenia
    View official trial listing →
  • Recruiting NCT NCT07093606

    Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

    Not yet reported Sohag University 100 participants Est. completion 2026-01-20 1 site Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Recruiting NCT NCT07421167

    A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

    Not yet reported Novartis Pharmaceuticals 164 participants Est. completion 2030-09-13 13 sites
    Other conditions: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
    View official trial listing →
  • Recruiting NCT NCT07587723

    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag

    Novartis Pharmaceuticals 150 participants Est. completion 2028-09-29 1 site
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Recruiting NCT NCT07788456

    Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 38 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00102726

    SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

    Not yet reported GlaxoSmithKline 183 participants Est. completion 2007-02 95 sites
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT00102739

    SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

    Not yet reported GlaxoSmithKline 99 participants Est. completion 2007-01 30 sites
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00110799

    SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

    Not yet reported GlaxoSmithKline 75 participants Est. completion 2006-11 30 sites
    Other conditions: Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00351468

    EXTEND (Eltrombopag Extended Dosing Study)

    Not yet reported Novartis Pharmaceuticals 302 participants Est. completion 2015-07 110 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00358540

    Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

    Not yet reported GlaxoSmithKline 18 participants Est. completion 2010-10-22 7 sites Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT00359463

    Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

    Not yet reported GlaxoSmithKline 33 participants Est. completion 2007-03-07 5 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00370331

    RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

    Not yet reported GlaxoSmithKline 197 participants Est. completion 2008-07 115 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00424177

    Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

    Not yet reported GlaxoSmithKline 66 participants Est. completion 2008-11 3 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00442871

    Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

    Not yet reported GlaxoSmithKline 29 participants Est. completion 2008-01-03 2 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00487968

    Eltrombopag Taste Testing in Healthy Adult Volunteers

    Not yet reported GlaxoSmithKline 12 participants 1 site
    Other conditions: Healthy Subjects, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00516321

    Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

    Not yet reported GlaxoSmithKline 687 participants Est. completion 2011-05 191 sites
    Other conditions: Hepatitis C, Chronic
    View official trial listing →
  • Completed NCT NCT00529568

    Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

    Not yet reported GlaxoSmithKline 759 participants Est. completion 2011-08 227 sites Stand-alone
    Other conditions: Hepatitis C, Chronic
    View official trial listing →
  • Completed NCT NCT00540423

    Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

    Not yet reported GlaxoSmithKline 23 participants Est. completion 2008-12 7 sites
    Other conditions: Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00643929

    LENS - Long-term Eltrombopag Observational Study

    GlaxoSmithKline 164 participants Est. completion 2013-03 71 sites
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Terminated NCT NCT00678587

    Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

    Not yet reported GlaxoSmithKline 292 participants Est. completion 2009-10 107 sites
    MASH Other conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
    View official trial listing →
  • Completed NCT NCT00688272

    Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

    Not yet reported GlaxoSmithKline 36 participants Est. completion 2008-09-25 1 site Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00828750

    Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

    Not yet reported GlaxoSmithKline 19 participants Est. completion 2011-02 6 sites Stand-alone
    Other conditions: Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT00833378

    Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

    Not yet reported GlaxoSmithKline 40 participants Est. completion 2009-03-11 1 site
    Other conditions: Hepatitis C
    View official trial listing →
  • Completed NCT NCT00861601

    Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

    Not yet reported GlaxoSmithKline 38 participants Est. completion 2009-08 10 sites Stand-alone
    Other conditions: Liver Diseases
    View official trial listing →
  • Completed NCT NCT00888901

    Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

    Not yet reported Ingrid Pabinger, MD 30 participants Est. completion 2011-05 Stand-alone
    Other conditions: Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Completed NCT NCT00902018

    Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

    Not yet reported Weill Medical College of Cornell University 20 participants Est. completion 2015-09-07 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00903422

    Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

    Not yet reported GlaxoSmithKline 98 participants Est. completion 2013-12-05 65 sites
    Other conditions: Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00903929

    Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

    Not yet reported Jane Liesveld 19 participants Est. completion 2015-12 Stand-alone
    Other conditions: Thrombocytopenia, Acute Radiation Syndrome
    View official trial listing →
  • Completed NCT NCT00908037

    Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

    Not yet reported GlaxoSmithKline 82 participants Est. completion 2014-02-01 33 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Terminated NCT NCT00909363

    Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

    Not yet reported Weill Medical College of Cornell University 24 participants Est. completion 2017-06-30 1 site Stand-alone
    Other conditions: Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
    View official trial listing →
  • Completed NCT NCT00922883

    A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 43 participants Est. completion 2018-04-24 1 site Stand-alone
    Other conditions: Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00961064

    A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 30 participants Est. completion 2021-12-30 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00996216

    Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

    Not yet reported GlaxoSmithKline 27 participants Est. completion 2013-02 28 sites Stand-alone
    Other conditions: Hepatitis C
    View official trial listing →
  • Completed NCT NCT01000051

    Eltrombopag for Post Transplant Thrombocytopenia

    Not yet reported M.D. Anderson Cancer Center 64 participants Est. completion 2018-04-04 1 site Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Withdrawn NCT NCT01055600

    Milk-only Lactation Study for Patients on Eltrombopag

    Not yet reported GlaxoSmithKline Est. completion 2014-07 1 site Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT01064336

    Promacta Pregnancy Registry

    GlaxoSmithKline 1 participants Est. completion 2014-07
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT01072162

    Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

    Not yet reported GlaxoSmithKline 40 participants Est. completion 2010-04-07 1 site Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT01098487

    A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

    Not yet reported GlaxoSmithKline 167 participants Est. completion 2014-05 34 sites Stand-alone
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Terminated NCT NCT01113502

    Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)

    Not yet reported, Not yet reported Abramson Cancer Center at Penn Medicine 44 participants Est. completion 2015-11-10 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT01133860

    Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 12 participants Est. completion 2010-06 3 sites Stand-alone
    Other conditions: Blood Platelet Disorders
    View official trial listing →
  • Completed NCT NCT01147809

    Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

    Not yet reported GlaxoSmithKline 130 participants Est. completion 2015-03 86 sites
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT01168921

    Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center 23 participants Est. completion 2022-03-07 1 site Stand-alone
    Other conditions: CLL, Leukemia
    View official trial listing →
  • Withdrawn NCT NCT01194167

    Study of Eltrombopag in Platelet Refractory Thrombocytopenia

    Not yet reported University of Cincinnati Est. completion 2012-01 1 site Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01235988

    Meta-analysis - Eltrombopag

    GlaxoSmithKline 1 participants Est. completion 2009-10
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT01236014

    Indirect Comparison Between Eltrombopag & Romiplostim

    GlaxoSmithKline 1 participants Est. completion 2009-10
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Terminated NCT NCT01286038

    Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 37 participants Est. completion 2018-11-03 1 site Stand-alone
    Other conditions: Myelodysplastic Syndrome (MDS), Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01286675

    Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT

    Not yet reported Dana-Farber Cancer Institute 19 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01328587

    Eltrombopag for Moderate Aplastic Anemia

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 34 participants Est. completion 2026-01-06 1 site Stand-alone
    Other conditions: Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
    View official trial listing →
  • Terminated NCT NCT01386723

    End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

    Weill Medical College of Cornell University 35 participants 1 site
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT01397149

    Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)

    Not yet reported, Not yet reported University of Ulm 4 participants Est. completion 2014-11 10 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01416311

    Drug Use Investigation for REVOLADE (ITP)

    Novartis Pharmaceuticals 5797 participants Est. completion 2020-10-16
    Other conditions: Purpura, Thrombocytopaenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT01428635

    Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2022-01-03 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Primary Myelofibrosis, Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT01433978

    A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

    Not yet reported Eisai Inc. 24 participants Est. completion 2013-09 1 site
    Other conditions: Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Completed NCT NCT01439321

    Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim

    GlaxoSmithKline 280 participants Est. completion 2011-06
    Other conditions: Immune Thrombocytopenic Purpura
    View official trial listing →
  • Completed NCT NCT01440374

    A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Not yet reported Novartis Pharmaceuticals 162 participants Est. completion 2015-12 120 sites Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Withdrawn NCT NCT01443351

    Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)

    Zealand University Hospital Est. completion 2019-08 1 site
    Other conditions: Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Completed NCT NCT01458080

    WEUSKOP5410: Observational Study in ENABLE Clinical Trials

    GlaxoSmithKline 1 participants Est. completion 2013-11
    Other conditions: Hepatitis C
    View official trial listing →
  • Completed NCT NCT01481220

    Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

    Not yet reported Nordic MDS Group 12 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Myelodysplastic Syndrome, Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT01484314

    Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 1 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Thrombocytopenia, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01488565

    A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia

    Not yet reported Peter MacCallum Cancer Centre, Australia 25 participants Est. completion 2015-05 2 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)
    View official trial listing →
  • Terminated NCT NCT01491594

    Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

    Not yet reported Duke University 1 participants Est. completion 2013-03 1 site
    Obstructive sleep apnea Other conditions: Sarcoma, Soft Tissue, Neoplasms, Connective and Soft Tissue
    View official trial listing →
  • Terminated NCT NCT01500538

    A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

    Not yet reported Peter MacCallum Cancer Centre, Australia 1 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01520909

    Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

    Not yet reported GlaxoSmithKline 92 participants Est. completion 2014-01 51 sites Stand-alone
    Other conditions: Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Terminated NCT NCT01550185

    Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported Roswell Park Cancer Institute 10 participants Est. completion 2014-12 2 sites Stand-alone
    Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01610180

    Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

    Not yet reported Fondazione Progetto Ematologia 18 participants Est. completion 2018-06-30 1 site
    Other conditions: Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Autoimmune Thrombocytopenia, Chronic Lymphocytic Leukemia, Non Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01618734

    Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

    Henri Mondor University Hospital 50 participants Est. completion 2012-06
    Other conditions: Immune Thrombocytopenia, Thrombopoietin Receptor Agonist
    View official trial listing →
  • Completed NCT NCT01621204

    A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

    Not yet reported McMaster University 74 participants Est. completion 2019-08 10 sites Stand-alone
    Other conditions: Immune Thrombocytopenic Purpura
    View official trial listing →
  • Active, not recruiting NCT NCT01623167

    Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

    Not yet reported, Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 207 participants Est. completion 2029-11-30 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT01636778

    Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

    Not yet reported GlaxoSmithKline 45 participants Est. completion 2014-11 16 sites
    Other conditions: Hepatitis C, Chronic
    View official trial listing →
  • Completed NCT NCT01652599

    Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 30 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Immune Thrombocytopenic Purpura
    View official trial listing →
  • Terminated NCT NCT01656252

    Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

    Not yet reported, Not yet reported PrECOG, LLC. 15 participants Est. completion 2016-03 5 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01657552

    Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

    Not yet reported GlaxoSmithKline 56 participants Est. completion 2012-10-26 1 site Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT01703169

    Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

    Not yet reported University of Utah 13 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia, Very Severe Aplastic Anemia, Moderate Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT01715779

    Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies

    Novartis 22 participants Est. completion 2015-06
    Other conditions: Hepatitis C
    View official trial listing →
  • Status unknown NCT NCT01757145

    Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation

    Not yet reported Rabin Medical Center 20 participants Est. completion 2016-06 2 sites Stand-alone
    Other conditions: Hematological Malignancy, Bone Marrow Failure Syndrome
    View official trial listing →
  • Completed NCT NCT01762761

    Eltrombopag Phase III Study In Chinese Chronic ITP Patients

    Not yet reported Novartis Pharmaceuticals 155 participants Est. completion 2018-11-22 18 sites Stand-alone
    Other conditions: Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
    View official trial listing →
  • Completed NCT NCT01772420

    Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

    Not yet reported Albert Einstein College of Medicine 52 participants Est. completion 2020-07-09 2 sites Stand-alone
    Other conditions: Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01791101

    Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 10 participants Est. completion 2020-06-26 16 sites Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT01821625

    Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 7 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Thrombocytopenia, Hepatitis C
    View official trial listing →
  • Completed NCT NCT01830660

    A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 96 participants Est. completion 2013-06 1 site
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT01864512

    Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment

    Shandong University Est. completion 2014-04 1 site
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01880047

    Safety and Efficacy of Eltrombopag at Escalated Doses

    Not yet reported Weill Medical College of Cornell University 35 participants Est. completion 2017-10-16 1 site
    Other conditions: Immune Thrombocytopenia, Platelet Disorder
    View official trial listing →
  • Completed NCT NCT01890746

    A Safety and Efficacy Study of Eltrombopag in Subjects With AML

    Not yet reported Novartis Pharmaceuticals 148 participants Est. completion 2017-01-25 42 sites Stand-alone
    Other conditions: Acute Leukaemia
    View official trial listing →
  • Completed NCT NCT01891994

    Extended Dosing With Eltrombopag for Severe Aplastic Anemia

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 40 participants Est. completion 2022-08-24 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia (SAA)
    View official trial listing →
  • Completed NCT NCT01893372

    Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

    Not yet reported M.D. Anderson Cancer Center 29 participants Est. completion 2019-01-06 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01927731

    Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

    Not yet reported M.D. Anderson Cancer Center 48 participants Est. completion 2023-06-06 1 site Stand-alone
    Other conditions: Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
    View official trial listing →
  • Status unknown NCT NCT01940562

    Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

    Not yet reported moshe yeshurun 20 participants Est. completion 2016-06 2 sites Stand-alone
    Other conditions: Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.
    View official trial listing →
  • Completed NCT NCT01957176

    A Rollover Study to Provide Continued Treatment With Eltrombopag

    Not yet reported Novartis Pharmaceuticals 22 participants Est. completion 2022-02-23 13 sites Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT01971684

    ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

    Boston Children's Hospital 120 participants Est. completion 2017-04 29 sites
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT01974232

    A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

    Weill Medical College of Cornell University 33 participants Est. completion 2013-06 1 site
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT02010645

    Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

    Not yet reported M.D. Anderson Cancer Center 6 participants Est. completion 2019-01-02 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02063763

    TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.

    Gruppo Italiano Malattie EMatologiche dell'Adulto 31 participants Est. completion 2015-02-26 14 sites
    Other conditions: Adult Patients, Immune Primary Thrombocytopenia, Splenectomy, TPO-mimetics
    View official trial listing →
  • Completed NCT NCT02071901

    Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

    Not yet reported Case Comprehensive Cancer Center 31 participants Est. completion 2019-01-06 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT02093325

    A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia

    Not yet reported Chang Gung Memorial Hospital 83 participants Est. completion 2019-08 3 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Completed NCT NCT02099747

    hATG+CsA vs hATG+CsA+Eltrombopag for SAA

    Not yet reported European Society for Blood and Marrow Transplantation 202 participants Est. completion 2020-12 29 sites Stand-alone
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT02148133

    A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

    Not yet reported Novartis Pharmaceuticals 21 participants Est. completion 2017-09-05 12 sites Stand-alone
    Other conditions: Cytopaenia
    View official trial listing →
  • Terminated NCT NCT02158936

    A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

    Not yet reported Novartis Pharmaceuticals 356 participants Est. completion 2016-04-30 155 sites Stand-alone
    Other conditions: Thrombocytopaenia
    View official trial listing →
  • Completed NCT NCT02201290

    A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2017-07-04 3 sites Stand-alone
    Other conditions: Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT02254434

    A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

    Not yet reported GlaxoSmithKline 26 participants Est. completion 2014-09-08 1 site Stand-alone
    Other conditions: Cirrhosis, Liver
    View official trial listing →
  • Completed NCT NCT02281370

    Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

    Not yet reported GlaxoSmithKline 39 participants Est. completion 2014-12-24 1 site Stand-alone
    Other conditions: Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT02298075

    Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

    Gruppo Italiano Malattie EMatologiche dell'Adulto 148 participants Est. completion 2019-04-17 13 sites
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT02323178

    A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

    Not yet reported, Not yet reported Groupe Francophone des Myelodysplasies 30 participants Est. completion 2021-04 26 sites Stand-alone
    Other conditions: CMML, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT02402998

    Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 55 participants Est. completion 2019-08-28 14 sites Stand-alone
    Other conditions: Primacy Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT02404025

    Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

    Not yet reported Novartis Pharmaceuticals 10 participants Est. completion 2017-09-06 11 sites Stand-alone
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT02422394

    Eltrombopag for Inherited Thrombocytopenias

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 24 participants Est. completion 2018-03 3 sites Stand-alone
    Other conditions: Inherited Platelet Disorder
    View official trial listing →
  • Terminated NCT NCT02446145

    A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients

    Not yet reported Technische Universität Dresden 132 participants Est. completion 2023-01-25 15 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02773225

    Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)

    Not yet reported, Not yet reported B. Höchsmann 93 participants Est. completion 2025-01-30 1 site Stand-alone
    Other conditions: Anemia, Aplastic
    View official trial listing →
  • Status unknown NCT NCT02834286

    Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 15 participants Est. completion 2017-09 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT02877212

    Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

    Not yet reported National Institute of Blood and Marrow Transplant (NIBMT), Pakistan 75 participants Est. completion 2017-09 1 site Stand-alone
    Other conditions: Immune Thrombocytopenic Purpura (ITP)
    View official trial listing →
  • Active, not recruiting NCT NCT02912208

    Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

    Not yet reported Associazione Qol-one 174 participants Est. completion 2026-10 64 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes, Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT02928419

    Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

    Not yet reported Associazione Qol-one 2 participants Est. completion 2018-09 50 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT02998645

    Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

    Not yet reported Novartis Pharmaceuticals 54 participants Est. completion 2022-05-30 20 sites Stand-alone
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT03025698

    A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

    Not yet reported Novartis Pharmaceuticals 51 participants Est. completion 2025-01-27 20 sites Stand-alone
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Active, not recruiting NCT NCT03206086

    Eltrombopag for Fanconi Anemia

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 25 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Completed NCT NCT03243656

    Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia

    Not yet reported Assiut University 20 participants Est. completion 2020-01-05 1 site
    Other conditions: Eltrombopag
    View official trial listing →
  • Completed NCT NCT03412188

    The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

    Not yet reported Nayera Hazaa Elsherif 36 participants Est. completion 2021-09-01 1 site Stand-alone
    Other conditions: Idiopathic Thrombocytopenic Purpura
    View official trial listing →
  • Status unknown NCT NCT03413306

    Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 100 participants Est. completion 2022-10-20 1 site Stand-alone
    Other conditions: Acquired Aplastic Anemia
    View official trial listing →
  • Status unknown NCT NCT03437603

    Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation

    Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2020-01 1 site Stand-alone
    Other conditions: Poor Graft Function
    View official trial listing →
  • Completed NCT NCT03515096

    Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

    Not yet reported Shenzhen Second People's Hospital 98 participants Est. completion 2022-07-01 1 site Stand-alone
    Other conditions: Eltrombopag, Hematopoietic Stem Cell Transplantation, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT03524612

    A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

    Not yet reported Novartis Pharmaceuticals 105 participants Est. completion 2022-10-03 32 sites
    Other conditions: Immune Thrombocytopenic Purpura (ITP)
    View official trial listing →
  • Active, not recruiting NCT NCT03603795

    Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

    Not yet reported French Innovative Leukemia Organisation 110 participants Est. completion 2026-07-30 15 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03638817

    Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

    Not yet reported University Hospital, Toulouse 13 participants Est. completion 2023-06-27 25 sites Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT03664518

    to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 48 participants Est. completion 2022-09-30 1 site Stand-alone
    Other conditions: Thrombocytopenia Purpura, Chronic HBV Infection
    View official trial listing →
  • Status unknown NCT NCT03701217

    Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 220 participants Est. completion 2019-10 1 site Stand-alone
    Other conditions: Eltrombopag, Thrombocytopenia, Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT03718533

    Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

    Not yet reported Novartis Pharmaceuticals 10 participants Est. completion 2020-11-03 7 sites Stand-alone
    Other conditions: Poor Graft Function
    View official trial listing →
  • Completed NCT NCT03754634

    A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

    Not yet reported Shandong University 30 participants Est. completion 2020-11-01 1 site Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT03771378

    Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 96 participants Est. completion 2020-05-15 1 site
    Other conditions: Primary Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT03830749

    Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

    Not yet reported Humanity & Health Medical Group Limited 53 participants Est. completion 2023-03-31 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT03896971

    Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia

    Not yet reported Safaa AA Khaled 66 participants Est. completion 2021-06-01 1 site
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Status unknown NCT NCT03902041

    The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

    Shandong Provincial Hospital 160 participants Est. completion 2022-10-01 1 site
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag
    View official trial listing →
  • Completed NCT NCT03939637

    Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

    Not yet reported Baylor College of Medicine 122 participants Est. completion 2025-02-26 27 sites Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT03948529

    RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation

    Not yet reported University Hospital, Lille 9 participants Est. completion 2023-08-21 1 site Stand-alone
    Other conditions: Leukemia, Graft Failure
    View official trial listing →
  • Completed NCT NCT03988608

    Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

    Not yet reported Novartis Pharmaceuticals 20 participants Est. completion 2023-05-17 5 sites Stand-alone
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Status unknown NCT NCT04102033

    Eltrombopag in Chronic ITP

    Not yet reported Assiut University 20 participants Est. completion 2021-01-01
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT04214951

    A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

    Peking University People's Hospital 100 participants Est. completion 2022-12 1 site
    Other conditions: Corticosteroid-resistant or Relapsed ITP
    View official trial listing →
  • Completed NCT NCT04269889

    Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

    Not yet reported, Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 15 participants Est. completion 2024-02-16 1 site Stand-alone
    Other conditions: Anemia, Diamond-Blackfan
    View official trial listing →
  • Status unknown NCT NCT04289207

    Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia

    Not yet reported Seoul National University Hospital 55 participants Est. completion 2021-03-01
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT04328727

    Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

    Not yet reported Novartis Pharmaceuticals 36 participants Est. completion 2024-12-06 12 sites Stand-alone
    Other conditions: Severe Aplastic Anemia (SAA)
    View official trial listing →
  • Completed NCT NCT04346654

    A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

    Not yet reported Novartis Pharmaceuticals 26 participants Est. completion 2023-09-22 10 sites Stand-alone
    Other conditions: Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Status unknown NCT NCT04371939

    Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 30 participants Est. completion 2023-07-30 1 site Stand-alone
    Other conditions: Wiskott-Aldrich Syndrome
    View official trial listing →
  • Completed NCT NCT04403321

    Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients

    Not yet reported Peking Union Medical College Hospital 114 participants Est. completion 2022-07-31 1 site Stand-alone
    Other conditions: Aplastic Anemia, Drug Effect
    View official trial listing →
  • Suspended NCT NCT04485416

    Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors

    Not yet reported University of California, Davis 10 participants Est. completion 2025-05-17 1 site Stand-alone
    Other conditions: Solid Tumor, Childhood, Solid Tumor
    View official trial listing →
  • Status unknown NCT NCT04516837

    Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)

    Not yet reported Peking University People's Hospital 120 participants Est. completion 2022-08 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT04518878

    Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)

    Not yet reported Peking University People's Hospital 30 participants Est. completion 2022-06 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT04542382

    Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)

    Not yet reported University of California, San Francisco 11 participants Est. completion 2023-08-11 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04638829

    Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

    Not yet reported Sobi, Inc. 60 participants Est. completion 2024-01-03 20 sites
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT04797000

    Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

    Not yet reported Novartis Pharmaceuticals 36 participants Est. completion 2026-12-09 20 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT04812483

    Immunomodulation With Eltrombopag in ITP

    Not yet reported University Children's Hospital Basel 2 participants Est. completion 2024-04-11 6 sites Stand-alone
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Available NCT NCT04837703

    Managed Access Programs for ETB115, Eltrombopag

    Novartis Pharmaceuticals
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT04915287

    Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

    Not yet reported Chinese PLA General Hospital 476 participants Est. completion 2023-07-31 1 site Stand-alone
    Other conditions: Thrombocytopenia; Drugs, Chronic Liver Disease
    View official trial listing →
  • Status unknown NCT NCT04915482

    TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 94 participants Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome, Connective Tissue Diseases
    View official trial listing →
  • Completed NCT NCT04917679

    Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

    Not yet reported Qilu Hospital of Shandong University 102 participants Est. completion 2022-06-01 1 site Stand-alone
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Enrolling by invitation NCT NCT05049668

    RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial

    European Society for Blood and Marrow Transplantation 197 participants Est. completion 2034-12 1 site
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Status unknown NCT NCT05286164

    Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

    Not yet reported Tel-Aviv Sourasky Medical Center 30 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: CART Treatment, B Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05369377

    Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

    Not yet reported Peking University People's Hospital 150 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT05438875

    The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

    Not yet reported Peking University People's Hospital 96 participants Est. completion 2024-11-30 5 sites Stand-alone
    Other conditions: Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Completed NCT NCT05466201

    The Use of Eltrombopag Post HSCT in BMFD

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 118 participants Est. completion 2025-10-31 1 site Stand-alone
    Other conditions: Stem Cell Transplant Complications
    View official trial listing →
  • Completed NCT NCT05583838

    A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 157 participants Est. completion 2024-07-16 17 sites
    Other conditions: Previously Treated Primary Immune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT05653219

    A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

    Not yet reported Novartis Pharmaceuticals 152 participants Est. completion 2028-04-08 74 sites Stand-alone
    Other conditions: Primary Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT05718856

    TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 166 participants Est. completion 2025-11-14 1 site Stand-alone
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Status unknown NCT NCT05861297

    Immune Thrombocytopenia Management in Adults

    Not yet reported Nahda University 467 participants Est. completion 2024-04-02 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia Purpura
    View official trial listing →
  • Not yet recruiting NCT NCT05907499

    Decitabine for Poor Graft Function Post Allo-HSCT

    Not yet reported The First Affiliated Hospital of Soochow University 76 participants Est. completion 2026-11-01 Stand-alone
    Other conditions: Poor Graft Function
    View official trial listing →
  • Completed NCT NCT05924152

    A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

    Not yet reported Mirati Therapeutics Inc. 16 participants Est. completion 2023-08-17 1 site
    Other conditions: Healthy Adults
    View official trial listing →
  • Completed NCT NCT06045052

    Eltrombopag for Treatment of Fanconi Anemia

    Not yet reported Julian Sevilla 8 participants Est. completion 2023-08-29 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Not yet recruiting NCT NCT06137105

    Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

    Assiut University 100 participants Est. completion 2026-12
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT06408324

    Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

    European Research Consortium on ITP 275 participants Est. completion 2024-04-05 17 sites
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Completed NCT NCT06458803

    Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

    Tongji Hospital 52 participants Est. completion 2023-11-19
    Other conditions: Refractory Thrombocytopenia, Connective Tissue Diseases
    View official trial listing →
  • Not yet recruiting NCT NCT06493981

    Outcomes in Bone Marrow Aplasia.

    Not yet reported Assiut University 3 participants Est. completion 2030-07 Stand-alone
    Other conditions: Aplastic Anemia Idiopathic
    View official trial listing →
  • Active, not recruiting NCT NCT06497036

    Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

    Not yet reported Geropharm 160 participants Est. completion 2028-03-31 6 sites Stand-alone
    Other conditions: Drug Effect, Safety Issues, Immunogenicity
    View official trial listing →
  • Not yet recruiting NCT NCT06607367

    REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2

    Not yet reported, Not yet reported Melbourne Health 20 participants Est. completion 2026-10-30 1 site Stand-alone
    Other conditions: Poor Graft Function, Aplastic Anemia Idiopathic
    View official trial listing →
  • Suspended NCT NCT06630221

    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

    Not yet reported Abhay Singh, MD MPH 25 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Completed NCT NCT06669221

    Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study

    Novartis Pharmaceuticals 1603 participants Est. completion 2023-11-03 1 site
    Other conditions: Aplastic Anemia (AA)
    View official trial listing →
  • Completed NCT NCT06768619

    Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 36 participants Est. completion 2023-04-27 1 site
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT06768632

    Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 36 participants Est. completion 2023-12-30 1 site
    Other conditions: Thrombocytopenia
    View official trial listing →
  • Not yet recruiting NCT NCT06790888

    Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 78 participants Est. completion 2027-12 Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT06834451

    Bioequivalence Study of Revolade® Eltrombopag 50 mg

    Not yet reported Centro de Atencion e Investigacion Medica 30 participants Est. completion 2025-10-30 1 site
    Other conditions: Healthy, Healthy Donors
    View official trial listing →
  • Completed NCT NCT06991894

    Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study

    Novartis Pharmaceuticals 2517 participants Est. completion 2024-05-17 1 site
    Other conditions: Anemia, Aplastic
    View official trial listing →
  • Not yet recruiting NCT NCT07001397

    Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

    Not yet reported Peking Union Medical College Hospital 70 participants Est. completion 2027-03-23
    Other conditions: Aplastic Anemias
    View official trial listing →
  • Completed NCT NCT07003269

    Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

    Haikou Affiliated Hospital of Central South University Xiangya School of Medicine 30 participants Est. completion 2026-04-30 1 site
    Other conditions: Thalassemia in Children
    View official trial listing →
  • Enrolling by invitation NCT NCT07102849

    Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study

    National Heart, Lung, and Blood Institute (NHLBI) 1400 participants Est. completion 2030-07-11 1 site
    Other conditions: Bone Marrow Failure Disorders, VEXAS Syndrome, Hemoglobinurea, Paroxysmal, Myelodysplastic Syndromes, Bone Marrow Diseases
    View official trial listing →
  • Enrolling by invitation NCT NCT07113743

    Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 10 participants Est. completion 2029-09-01 1 site Stand-alone
    Other conditions: Chronic Granulomatous Disease (CGD)
    View official trial listing →
  • Not yet recruiting NCT NCT07189910

    Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 150 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Not yet recruiting NCT NCT07198672

    Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

    Not yet reported Zhenzhen Liu 45 participants Est. completion 2028-10-31 Stand-alone
    Other conditions: HER2-positive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07297550

    Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 42 participants Est. completion 2027-07-01 Stand-alone
    Other conditions: Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT07415083

    A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

    Novartis Pharmaceuticals 13 participants Est. completion 2025-02-25 1 site
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Not yet recruiting NCT NCT07476846

    rhTPO Dose Escalation vs Eltrombopag Switch in ITP

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 112 participants Est. completion 2028-03
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Withdrawn NCT NCT07523009

    CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA

    Not yet reported Peking Union Medical College Hospital Est. completion 2029-12 Stand-alone
    Other conditions: Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia
    View official trial listing →
  • Not yet recruiting NCT NCT07558434

    CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

    Not yet reported Peking Union Medical College Hospital 43 participants Est. completion 2029-12 Stand-alone
    Other conditions: Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia
    View official trial listing →
  • Not yet recruiting NCT NCT07660172

    A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.

    Not yet reported Novartis Pharmaceuticals 36 participants Est. completion 2033-04-22 Stand-alone
    Other conditions: Primary Immune Thrombocytopenia (ITP)
    View official trial listing →
  • Not yet recruiting NCT NCT07669675

    TPO-RA Plus Baricitinib vs. TPO-RA for ITP

    Not yet reported Peking University People's Hospital 100 participants Est. completion 2028-08-31 Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Not yet recruiting NCT NCT07687134

    Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Eltrombopag Olamine, Eltrombopag, EPAG

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.